Bristol’s Opdivo Joins Keytruda, Imfinzi In Perioperative NSCLC Treatment Space

PD-1 inhibitor Opdivo has obtained US FDA approval for pre- and post-surgical treatment in operable non-small cell lung cancer, but Merck and AstraZeneca got there first.